Haemonetics (HAE) vs Insulet (PODD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Haemonetics (HAE) has outperformed Insulet (PODD) over the past year, gaining 106.5% versus a loss of 57.1%. Over five years, HAE leads with a +45.5% price change compared with -55.3% for PODD. Insulet is the larger company by market cap ($9.25 billion vs $5.36 billion), about 1.7 times the size.
On valuation, Insulet trades at a lower forward P/E (17.3x vs 20.4x for Haemonetics). Insulet converts more of its revenue into profit, with a net margin of 9.1% versus 7.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | PODD |
|---|---|---|
| Share price | $117.75 | $133.38 |
| Market cap | $5.36B | $9.25B |
| 1-day change | +15.77% | -0.73% |
| YTD return | +26.90% | -52.73% |
| 1-year return | +106.48% | -57.14% |
| 5-year return | +45.49% | -55.29% |
| P/E ratio (TTM) | 56.88 | 24.98 |
| Forward P/E | 20.38 | 17.25 |
| EPS (TTM) | $2.07 | $5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $2.71B |
| Revenue growth (YoY) | -1.97% | +30.73% |
| Net income (latest FY) | $97.31M | $247.10M |
| Gross margin | 59.04% | 71.63% |
| Operating margin | 11.75% | 17.50% |
| Net margin | 7.29% | 9.12% |
| 52-week high | $120.72 | $354.88 |
| 52-week low | $48.17 | $126.40 |
| Distance from 52-week high | -2.46% | -62.42% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -5.31% | +28.18% |
| Average volume | 678.94K | 1.68M |
| Shares outstanding | 45.50M | 69.35M |
| Employees | 3,009 | 5,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed PODD by 163.6 percentage points over the past year.
- Haemonetics trades at a higher earnings multiple (56.9x vs 25.0x trailing P/E).
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs -1.97%).
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
HAE vs PODD FAQ
Which is bigger, Haemonetics or Insulet?
Insulet (PODD) is larger, with a market capitalization of $9.25B compared with $5.36B for Haemonetics (HAE).
Which stock has performed better over the past year, HAE or PODD?
HAE returned +106.48% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HAE or PODD?
PODD has the lower trailing P/E at 25.0, versus 56.9 for HAE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Haemonetics and Insulet in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.